UK Pharma News Roundup May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
Address: First Floor, Building 2,
Croxley Green Business Park,
Marlins Meadows
Watford, Hertfordshire
United Kingdom – WD18 8YA
Tel: +44 (0) 1923 202 950
Web: http://eu.glenmark-generics.com/
Glenmark Generics (Europe) Ltd headquartered in the UK operates through its own sales infrastructure in the UK and through licensing & distribution arrangements in other European markets.
The UK office based in Hatfield, Hertfordshire possesses the infrastructure to support licensing, regulatory submissions, project management, distribution of sales in the UK and across Europe.
Glenmark is building its presence in markets across Europe and seeks out opportunities to develop strategic alliances and marketing collaborations with leading generic companies operating in the EU markets.
Glenmark was awarded the prestigious SCRIP award in 2008 for the Best Pharma company in the world – SME & the Best Company in Emerging Markets.
Glenmark Generics (Europe) Ltd has an exciting portfolio of 5 approved products, 12 products filed and pending approval; with a further 15 products in development. These are solid and semi-solid products filed as EU CTD dossiers and offered for out-licensing to prospective partners. Most of the portfolio are backed up with vertical integration on APIs.
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
The 9th February 2019 marked the launch of the European Medicines Verification System (EMVS) which will use cutting-edge technology to safeguard the medicine supply chain against fake products. Each European country…
In recent years, apocalyptic conversations around superbugs caused by antimicrobial resistance (AMR) have been on the up, but just in case we were becoming immune to these warnings, the UK has…
An unusual characteristic of the UK’s healthcare landscape is that charities fund the vast majority of medical research. According to the Association of Medical Research Charities (AMRC), in 2017, 8 million people…
See our Cookie Privacy Policy Here
